Tectonic Therapeutic Named an "Endpoints 11" Winner

Tectonic Therapeutic, a pre-clinical stage biotechnology company transforming the discovery of novel G-protein-coupled receptors (GPCR)-targeted therapies, today announced that it has been named as one of the Endpoints 11 most promising private startups in biotech. Selected by Endpoints News founder and editor John Carroll, the Endpoints 11 recognizes biotech companies that are poised to develop new and impactful medicines: an outstanding team, a transformative approach/platform, and substantial capital.

Tectonic's novel approach has the potential to unlock the full therapeutic utility of GPCRs. GCPRs are central to human biology and are the target of approximately a third of all approved drugs for treating a wide range of diseases. Yet, GPCRs remain a large untapped opportunity as many receptors remain unexplored or are undruggable by small molecules. Instead of using small molecules, Tectonic is taking a biologic approach with their GEODetm platform that is designed to overcome the challenges encountered to date in GPCR biologic discovery campaigns. A biologic approach will address major challenges by increasing specificity and by facilitating the targeting of GPCRs whose natural ligands are peptides or proteins.

"We are honored to be recognized as one of the Endpoints 11 companies for our work in transforming the discovery of novel GPCR-targeted therapies," said Alise Reicin, MD, President and Chief Executive Officer, Tectonic Therapeutic. "This award supports our biologic approach via our GEODetm platform to blaze a new trial for GPCR therapy; it further strengthens our excitement and resolution to bring our science to a wide range of patients in need."

"This year more than ever before we're seeing biotechs raise unprecedented amounts of money to pursue dramatic new gains in therapeutics," says John Carroll, the founding editor of Endpoints. "But money isn't enough. The Endpoints 11 is a list of companies with a shot at doing something big ? and they're taking on some big risks in a swing for the fences."

About Tectonic Therapeutic

Tectonic, co-founded by Andrew Kruse and Tim Springer of Harvard Medical School, is transforming the discovery of antibodies and other biologic drugs targeting G-protein Coupled Receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. With our proprietary GEODe platform, we aim to unlock the therapeutic utility of the most difficult receptors in the class, to date considered undruggable with small molecules. For more information, please visit www.tectonictx.com, or follow us on LinkedIn.